Silence Therapeutics plc
NASDAQ:SLN · NASDAQ Global Market
+$0.19 today
Vol 0.38M · Avg 0.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-142.2%
avg -142.2%
ROIC
-76.1%
avg -42.6%
ROA
-67.4%
avg -33.4%
Analysis
ROA is currently the strongest return metric at -67.4% versus its period average of -33.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director | $512,932.00 | — | 55 | $375,000.00 | 0.79% |
Steven J. Romano | Executive Vice President and Chief Research & Development Officer | $496,667.00 | — | 67 | $300,000.00 | 0.64% |
Iain Gladstone Ross | Interim CEO & Chairman of the Board | $481,912.00 | — | 72 | $900,000.00 | 1.91% |
Marie Wikstrom Lindholm | Chief Scientific Officer | — | — | — | — | — |
Curtis Rambaran | Chief Medical Officer | — | — | — | — | — |
Gabriel | Chief Technical Operations Officer | — | — | — | — | — |
Gem Gokmen Hopkins | Head of IR & Corporation Communications | — | — | — | — | — |
Gianine Esposito | Chief Human Resources Officer | — | — | — | — | — |
Jaimin Shah | SVP & General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
21
$2.63M
Sells
0
$0.00
Net Sentiment
+$2.63M
Net buying
Most Active
Griffiths Richard Ian
21 transactions
1–10 of 21
Analysis
Insiders reported 21 buys worth $2.63M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.63M. Griffiths Richard Ian was the most active insider with 21 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.30B
Alto Neuroscience, Inc.
NYSE:ANRO
$782.59M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$443.03M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$389.86M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$348.58M
Amarin Corporation plc
NASDAQ:AMRN
$332.17M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$292.84M
AC Immune S.A.
NASDAQ:ACIU
$241.71M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.02M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.52M
Who manages SLN?
Silence Therapeutics plc (SLN) lists 9 active executives. The top listed executive is Marie Wikstrom Lindholm, Chief Scientific Officer.
Are SLN insiders buying or selling?
Recent insider activity shows net buying of $20.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.